4-methyl-9H-fluoren-9-one | 4269-05-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 4-methyl-9H-fluoren-9-one
• 英文别名: 4-Methyl-fluorenon；4-methylfluorenone；4-methylfluoren-9-one；Methylfluorenone
• CAS: 4269-05-0
• 化学式: C₁₄H₁₀O
• 分子量: 194.233
• InChiKey: QCVMLXNTSUFLGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914399090

反应信息

• 作为反应物：
  描述：

  4-methyl-9H-fluoren-9-one 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以96%的产率得到4-甲基-9H-芴-9-醇
  参考文献：
  名称：

  Electronic effects on the substitution reactions of benzhydrols and fluorenyl alcohols. Determination of mechanism and effects of antiaromaticity

  摘要：

  将联苯酚融合成氟酚，发现它并不影响取代反应的电子敏感性，这表明中间体的反芳香性仅用于减慢过程。

  DOI：

  10.1039/c5ob01637a
• 作为产物：
  描述：

  2-甲基联苯-2-甲醛 在 叔丁基过氧化氢 、 二茂铁 作用下， 以 癸烷 、 乙腈 为溶剂， 反应 24.0h， 以56%的产率得到4-methyl-9H-fluoren-9-one
  参考文献：
  名称：

  通过碱促进的均质芳香取代（BHAS）进行的交叉脱氢偶联：芴酮和氧杂蒽酮的合成

  摘要：

  报道了通过碱促进的均相芳族取代（BHAS）发生的交叉脱氢偶联反应。可以通过CDC容易地分别从容易获得的邻甲酰基联苯和邻甲酰基联苯醚开始制备芴酮和氧杂蒽。市售和廉价的t BuOOH被用作氧化剂。用少量的FeCp 2（0.1或1 mol％）可以最好地实现自由基链反应的引发。

  DOI：

  10.1021/ol4000857

文献信息

• Rapid Formation of Fluoren-9-ones via Palladium-Catalyzed External Carbon Monoxide-Free Carbonylation
  作者：Hideyuki Konishi、Suguru Futamata、Xi Wang、Kei Manabe

  DOI：10.1002/adsc.201800155

  日期：2018.5.2

  carbonylation reaction for the synthesis of fluoren‐9‐ones from 2‐halogenated biphenyls using phenyl formate as a carbon monoxide surrogate was achieved. The combined use of cesium carbonate and o‐anisic acid resulted in a remarkable rate enhancement, where the reaction was complete within 3 min in some cases. Mechanistic studies indicated that the turnover‐limiting step of the reaction was the C−H bond‐cleaving

  在甲酸苯酯作为一氧化碳替代物的条件下，实现了钯催化的羰基化反应，由2-卤代联苯合成氟-9-酮。碳酸铯和邻茴香酸的组合使用可显着提高速率，在某些情况下，反应可在3分钟内完成。机理研究表明，取决于所用的底物，反应的周转限制步骤是CH键裂解步骤或氧化加成步骤。
• Access to Atropisomerically En­riched Biaryls by the Coupling of Aryllithiums with Arynes under Control by Homochiral Oxazolines
  作者：Boubacar Yalcouye、Anaïs Berthelot-Bréhier、David Augros、Armen Panossian、Sabine Choppin、Matthieu Chessé、Françoise Colobert、Frédéric R. Leroux

  DOI：10.1002/ejoc.201501503

  日期：2016.2

  We report the preparation of axially stereoenriched biphenyls by the coupling of in situ generated aryllithiums and arynes using chiral oxazoline auxiliaries. The design of the aryne precursors, the choice of oxazoline and the reaction conditions were key to accessing the desired, highly substituted, atropisomerically enriched biarylic products. In one case, the two atropo-diastereomers could be obtained

  我们报告了通过使用手性恶唑啉助剂将原位生成的芳基锂和芳烃偶联来制备轴向立体富集的联苯。芳炔前体的设计、恶唑啉的选择和反应条件是获得所需的、高度取代的、富含阻转异构的二芳基产物的关键。在一种情况下，可以通过柱色谱分离和通过 X 射线晶体学建立的绝对构型以异构纯形式获得两种阻滞非对映体。反应的立体选择性似乎受微妙的参数控制。
• Atropo-diastereoselective coupling of aryllithiums and arynes — variations around the chiral auxiliary
  作者：David Augros、Boubacar Yalcouye、Anaïs Berthelot-Bréhier、Matthieu Chessé、Sabine Choppin、Armen Panossian、Frédéric R. Leroux

  DOI：10.1016/j.tet.2016.01.047

  日期：2016.8

  The atropo-selective coupling of in situ generated arynes and aryllithiums bearing various chiral auxiliaries ortho to lithium (tert-butylsulfoxide, para-tolylsulfoxide, tartrate-derived chiral diethers and oxazolines) is described. Chiral oxazolines showed the best results in terms of yields of coupling products. Different reaction parameters like the nature of the aryne precursor, the oxazoline,

  描述了在原位生成的芳烃和芳基锂的对位选择性偶联，所述芳烃和芳基锂带有与锂邻位的各种手性助剂（叔丁基亚砜，对甲苯基亚砜，酒石酸酯衍生的手性二醚和恶唑啉）。就偶联产物的产率而言，手性恶唑啉显示出最佳结果。揭示了不同的反应参数，如芳烃前体，恶唑啉，烷基锂碱或溶剂的性质，对于获得良好的收率和非对映选择性至关重要。
• Tricylic amino-acid derivatives
  申请人：Allelix Neuroscience Inc.

  公开号：US06162824A1

  公开（公告）日：2000-12-19

  Described herein are compounds which have the general formula: ##STR1## or a prodrug or pharmaceutically acceptable salt, solvate or hydrate thereof wherein: R.sup.1 is selected from the group consisting of H, alkyl and the counter ion for a basic addition salt; X is selected from the group consisting of CR.sup.9 R.sup.10, S, O, SO, SO.sub.2, NH and N-alkyl; R.sup.2, R.sup.3, R.sup.4, R.sup.9 and R.sup.10 are independently selected from the group consisting of H and alkyl; R.sup.5 and R.sup.6 are independently selected from the group consisting of H, alkyl and phenyl, or, alternatively, R.sup.5 and R.sup.6 together may form a methylene group or a 3- to 6-membered a spirocyclic group; wherein, when X is CR.sup.9 R.sup.10, one or both pairs of R.sup.5 and R.sup.9 or R.sup.6 and R.sup.10 may join to form a double or triple bond R.sup.7 is selected from the group consisting of Formula II-V: ##STR2## which are all optionally substituted, at nodes other than R.sup.8, with 1-4 substituents independently selected from the group consisting of alkyl, halo, aryl (which may be substituted as for R.sup.8), trifluoromethyl, trifluoromethoxy, nitro, cyano, amino, mono-alkylamino, di-alkylamino, alkoxycarbonyl, alkylcarbonyl, alkoxythiocarbonyl, alkylthiocarbonyl, alkoxy, alkylS-, phenoxy, --SO.sub.2 NH.sub.2, --SO.sub.2 NHalkyl, --SO.sub.2 N(alkyl).sub.2 and 1,2-methylenedioxy; and wherein any of the benzo-fused rings in structures II to V may be replaced by a 5- or 6-membered heterocyclic ring selected from the group consisting of pyridine, thiophene, furan and pyrrole; wherein R.sup.8 is selected from the group consisting of H, alkyl, benzyl, cycloalkyl, indanyl and an optionally substituted aryl group, wherein the optional substituents are independently selected from 1-4 members of the group consisting of alkyl, halo, aryl, trifluoromethyl, trifluoromethoxy, nitro, cyano, amino, mono-alkylamino, di-alkylamino, alkoxycarbonyl, alkylcarbonyl, alkoxythiocarbonyl, alkylthiocarbonyl, alkoxy, alkylS-, phenoxy, --SO.sub.2 NH.sub.2, --SO.sub.2 NHalkyl, --SO.sub.2 N(alkyl).sub.2 and 1,2-methylenedioxy; --represents a single or double bond; Y is selected from the group consisting of O, S, SO, NH, N-alkyl, CH.sub.2, CH-alkyl, C(alkyl).sub.2, and C.dbd.O; Z is selected from the group consisting of CH.sub.2, O, S, NH and N-alkyl when--is a single bond; Z is selected from the group consisting of CH and N when--is a double bond. Also described is the use of these compounds as pharmaceuticals.

  本文描述了具有以下一般式的化合物：##STR1##或其前药或药用可接受的盐、溶剂或水合物，其中：R.sup.1选自H、烷基和碱性加成盐的对离子组成的群；X选自CR.sup.9 R.sup.10、S、O、SO、SO.sub.2、NH和N-烷基的群；R.sup.2、R.sup.3、R.sup.4、R.sup.9和R.sup.10独立地选自H和烷基的群；R.sup.5和R.sup.6独立地选自H、烷基和苯基，或者，作为另一选择，R.sup.5和R.sup.6可以一起形成亚甲基基团或3-至6-成员的螺环基团；当X为CR.sup.9 R.sup.10时，R.sup.5和R.sup.9或R.sup.6和R.sup.10中的一个或两个对可能连接以形成双键或三键R.sup.7选自以下式II-V的群：##STR2##它们都可以在除R.sup.8之外的节点上选择性地取代，取代基独立地选自烷基、卤素、芳基（可能像R.sup.8那样被取代）、三氟甲基、三氟甲氧基、硝基、氰基、氨基、单烷基氨基、双烷基氨基、烷氧羰基、烷基羰基、烷氧硫代羰基、烷基硫代羰基、烷氧基、烷基硫、苯氧基、--SO.sub.2 NH.sub.2、--SO.sub.2 NH烷基、--SO.sub.2 N(烷基).sub.2和1,2-亚甲二氧基；结构II至V中的苯并环中的任何一个都可以被选择自吡啶、噻吩、呋喃和吡咯的5-或6-成员杂环环取代；其中R.sup.8选自H、烷基、苄基、环烷基、茚基和一个可选择性取代的芳基，其中可选择性取代基独立地选自烷基、卤素、芳基、三氟甲基、三氟甲氧基、硝基、氰基、氨基、单烷基氨基、双烷基氨基、烷氧羰基、烷基羰基、烷氧硫代羰基、烷基硫代羰基、烷氧基、烷基硫、苯氧基、--SO.sub.2 NH.sub.2、--SO.sub.2 NH烷基、--SO.sub.2 N(烷基).sub.2和1,2-亚甲二氧基；--表示单键或双键；Y选自O、S、SO、NH、N-烷基、CH.sub.2、CH-烷基、C(烷基).sub.2和C.dbd.O的群；当--为单键时，Z选自CH.sub.2、O、S、NH和N-烷基的群；当--为双键时，Z选自CH和N的群。还描述了这些化合物作为药物的用途。
• 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS
  申请人：Figueroa Perez Santiago

  公开号：US20100035902A1

  公开（公告）日：2010-02-11

  The present application relates to novel aryl-substituted heterobicyclic compounds, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

  本申请涉及新颖的芳基取代杂双环化合物，其制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制造治疗和/或预防疾病的药物，特别是心血管疾病。

表征谱图